4D Molecular Therapeutics (FDMT) Operating Margin (2020 - 2025)
Historic Operating Margin for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Q3 2025 value amounting to 67983.33%.
- 4D Molecular Therapeutics' Operating Margin rose 16364166700.0% to 67983.33% in Q3 2025 from the same period last year, while for Sep 2025 it was 191982.5%, marking a year-over-year increase of 7984645600.0%. This contributed to the annual value of 507678.38% for FY2024, which is 5071337300.0% down from last year.
- As of Q3 2025, 4D Molecular Therapeutics' Operating Margin stood at 67983.33%, which was up 16364166700.0% from 396373.33% recorded in Q2 2025.
- 4D Molecular Therapeutics' 5-year Operating Margin high stood at 192905.26% for Q4 2023, and its period low was 5611700.0% during Q4 2024.
- Its 5-year average for Operating Margin is 475592.34%, with a median of 13446.03% in 2023.
- Its Operating Margin has fluctuated over the past 5 years, first crashed by 2000000000bps in 2024, then soared by 2000000000bps in 2025.
- 4D Molecular Therapeutics' Operating Margin (Quarter) stood at 26917.39% in 2021, then surged by 91bps to 2303.13% in 2022, then surged by 8476bps to 192905.26% in 2023, then tumbled by -3009bps to 5611700.0% in 2024, then soared by 99bps to 67983.33% in 2025.
- Its last three reported values are 67983.33% in Q3 2025, 396373.33% for Q2 2025, and 383007.14% during Q1 2025.